Veeva Systems Inc - Class A NYSE:VEEV Price, Chart, News & Insight

NYSE:VEEV

Veeva Introduces Falcon Safety AI Platform to Automate Drug Safety Operations

Veeva Systems (NYSE: VEEV) announced Tuesday Veeva Falcon Safety, a new agentic AI product designed to automate and streamline pharmacovigilance operations for biopharmaceutical companies.

Falcon Safety will support adverse-event intake, case processing and follow-up, with the goal of reducing operating costs and processing times while maintaining regulatory compliance. The product is part of Veeva AI, the company’s portfolio of industry-specific artificial intelligence solutions for life sciences.

Importantly, Falcon Safety will not be limited to customers using Veeva’s own Safety platform. The product is designed to work with any E2B-compliant safety system, including competing platforms such as Oracle Argus and ArisGlobal LifeSphere MultiVigilance, and across different adverse-event intake channels.

That interoperability could significantly expand Falcon Safety’s addressable market by allowing pharmaceutical companies to adopt Veeva’s AI capabilities without replacing their existing pharmacovigilance infrastructure.

The launch also demonstrates how Veeva is extending AI deeper into specialized, highly regulated life-sciences workflows, where automation can potentially generate meaningful productivity improvements. Falcon Safety is scheduled to become available to early adopters in November 2026.

💬

WS Investor 09-01-26

Veeva Systems Jumps 8% Premarket as AI Momentum and Strong Q2 Results Lift Outlook

Veeva Systems (NYSE: VEEV) shares are up about 8% in premarket trading after the life sciences software company reported fiscal second-quarter results above its guidance across all key metrics and raised its full-year outlook.

Revenue increased 18% year over year to $928 million, while subscription revenue rose 16% to $766.8 million. Profitability grew even faster, with GAAP operating income jumping 40% to $275 million. Non-GAAP EPS increased to $2.35 from $1.99 a year earlier.

AI and Vault CRM strengthen growth story

Investor enthusiasm also appears tied to Veeva's accelerating AI strategy. Vault CRM recorded its best quarter ever, while the company said development of its Veeva Falcon agentic AI platform is progressing rapidly. Falcon currently has five early adopters and remains on track for initial deployments this year.

Vault CRM adoption continues to expand, with more than 180 customers live and commitments from 12 of the world's top 20 biopharma companies.

Management said its full-year outlook improved across the board. Veeva now expects FY2027 revenue of $3.682 billion-$3.687 billion, non-GAAP operating income of approximately $1.64 billion and non-GAAP EPS of about $9.21.

The 8% premarket rally appears driven by the combination of better-than-guided results, strong subscription growth, expanding margins and growing evidence that Veeva's AI products could become an important new growth engine within its already strong life sciences software franchise.

💬

European Investor 08-27-26

Veeva Systems Stock Rises 3.1% as Barclays Raises Price Target to $275

Veeva Systems (NYSE: VEEV) shares are up 3.1% after Barclays raised its price target on the cloud software company, providing a positive catalyst as the firm maintained its Overweight rating.

Barclays analyst Saket Kalia increased the price target for Veeva Systems from $235 to $275. With Veeva trading around $245.65, the new target implies approximately 12% upside.

Why the Barclays Target Increase Is Positive for Veeva

The size of the revision is notable. Barclays lifted its target by $40, or roughly 17%, while retaining its bullish Overweight recommendation. The new $275 target is also comfortably above the stock's price in the report, indicating that Barclays continues to see additional upside even after today's 3.1% gain.

Veeva occupies a distinctive position within the enterprise software sector because of its specialization in cloud applications for the life sciences industry. Its products support pharmaceutical and biotechnology companies across areas including clinical development, regulatory processes, quality management, safety, medical affairs and commercial operations.

This vertical specialization creates a relatively strong competitive position. Life sciences customers operate in highly regulated environments, making industry-specific software, data management and regulatory capabilities particularly important. Once these systems become embedded in customers' workflows, switching providers can also become operationally complex.

## AI and Life Sciences Software Provide Longer-Term Growth Opportunities

Veeva is also positioned at the intersection of enterprise software, healthcare technology and the broader digital transformation of pharmaceutical development. Increasing use of data analytics and AI across drug development and commercial operations could expand demand for integrated cloud platforms capable of managing increasingly complex life-sciences workflows and data.

Unlike more general enterprise software companies, Veeva's concentration on life sciences gives investors relatively direct exposure to technology spending within pharmaceutical and biotechnology companies.

Barclays' decision to raise its target from $235 to $275 while maintaining an Overweight rating reinforces that growth thesis. With the new target implying about 12% upside from $245.65, the analyst action appears to be a key factor supporting Veeva Systems shares today.

💬

European Investor 08-18-26

Veeva Systems Expands Lilly Partnership With Global Vault CRM Rollout

Veeva Systems (NYSE: VEEV) announced that Eli Lilly and Company has selected Veeva Vault CRM for deployment across its global operations, expanding the companies’ existing strategic relationship.

Vault CRM is part of Veeva’s CRM Suite and is designed to support an AI-enabled commercial model for life sciences companies. The platform combines CRM applications, data and agentic AI capabilities aimed at improving interactions between pharmaceutical companies and healthcare professionals.

Lilly said the transition to Vault CRM will support its efforts to bring new medicines to more patients worldwide.

The selection represents a significant customer win for Veeva given Lilly’s scale as a global pharmaceutical company. It also reinforces Veeva’s position in life-sciences cloud software as the company expands AI capabilities across its commercial platform.

💬

The Investor 08-11-26

Veeva Falls 5% Despite Strong Earnings Beat, Raised Guidance and Accelerating AI Strategy

Veeva Systems (VEEV) fell 5% in premarket trading despite reporting another strong quarter that exceeded expectations across revenue, earnings, and profitability metrics while raising full-year guidance. The decline suggests investors may have entered earnings with exceptionally high expectations given Veeva's strong positioning in healthcare software and artificial intelligence.

The life sciences cloud software leader reported first-quarter revenue of $882.9 million, up 16% year-over-year, while subscription revenue grew 15% to $730.2 million. Profitability remained outstanding, with operating income rising 17% to $273.1 million and diluted earnings per share increasing 15% to $1.57. Non-GAAP earnings per share reached $2.24, comfortably ahead of the prior year's $1.97.

Management highlighted broad-based growth across its business and continued momentum in both its commercial and development cloud offerings. One of the most notable achievements was the addition of 27 new Vault CRM customers during the quarter, bringing the total number of live customers to more than 150 as Veeva continues replacing legacy CRM systems throughout the pharmaceutical industry.

Investors were also encouraged by rapid progress in the company's AI initiatives. Following the acquisition of Ostro, Veeva now provides conversational AI solutions to more than 50 pharmaceutical brands. Management also announced that Vault AI is scheduled to expand across all Vault applications later this year, while Veeva Falcon, its new agentic AI platform for clinical, regulatory, and safety workflows, is expected to begin early adopter deployment in November.

Reflecting the strong quarter, Veeva raised its full-year fiscal 2027 outlook. The company now expects revenue of $3.64 billion, non-GAAP operating income of approximately $1.61 billion, and non-GAAP earnings per share of about $9.05. Management emphasized that customer interest in AI-powered productivity solutions continues to grow rapidly across the life sciences industry.

Despite these positives, investors may have been looking for an even larger increase to guidance given the company's strong execution and growing AI opportunity. Veeva's shares have historically traded at premium valuations due to its dominant market position, high margins, recurring revenue model, and consistent growth. In such cases, even excellent results can trigger selling if they fail to substantially exceed already elevated expectations.

Importantly, there was little in the report to indicate any operational weakness. Revenue growth remained healthy, margins stayed exceptionally strong, guidance was raised, and AI adoption appears to be accelerating. The stock's decline appears driven more by valuation and investor expectations than by any deterioration in the company's business fundamentals.

Overall, Veeva delivered another high-quality quarter with strong growth, expanding AI capabilities, increasing customer adoption, and higher guidance. The premarket weakness appears to reflect a market that expected perfection from one of the software sector's most highly regarded companies.

💬

The Investor 06-04-26

5 Cash-Rich Fortresses with War Chests That Could Withstand the Market Chaos

Uncover the 5 cash-rich fortresses built to survive market turbulence and geopolitical tensions with strong war chests.

(thesmartinvestor.com.sg)

💬

European Investor 04-09-26

Veeva Systems announced the acquisition of Ostro, an AI-driven brand engagement platform for the life sciences industry, in a deal valued at approximately $100 million in cash and equity retention grants.

Ostro’s technology enables pharmaceutical brands to provide patients and healthcare professionals with real-time answers through AI-powered chat interfaces on brand websites. The platform uses conversational AI, semantic search and industry-specific compliance controls to deliver responses drawn from approved medical, legal and regulatory (MLR) materials.

Following the acquisition, Ostro will operate as an independent unit led by its CEO Chase Feiger. Veeva plans to integrate Ostro over time with its Commercial Cloud applications to connect digital engagement with field sales and medical interactions, helping life sciences companies improve customer engagement and access to trusted health information.
PRNewswire

💬

European Investor 03-10-26

Veeva Systems announced that AOP Health will standardize its global operations on the Veeva Industry Cloud for Life Sciences to connect research, development, quality, commercial and data functions on a single platform.

By adopting applications across the Veeva Vault Platform—including Development Cloud, Quality Cloud, Commercial Cloud and Data Cloud—AOP Health aims to streamline operations, eliminate data silos and accelerate the development and delivery of treatments for rare diseases and critical care conditions.

The unified platform will support collaboration across clinical, regulatory, safety and quality teams while improving coordination between commercial and medical functions. Veeva said the integrated cloud strategy will help AOP Health scale globally and speed the delivery of therapies to patients.
PRNewswire

💬

European Investor 03-10-26

Veeva Systems Inc. (NYSE: VEEV) announced that more than 125 customers worldwide are now live on its next-generation Vault CRM platform, marking growing adoption of its AI-enabled customer relationship management system for the life sciences industry.

The customers include several top 20 biopharmaceutical companies as well as organizations across the United States, Europe, and Japan. Vault CRM is designed to support commercial and medical teams throughout the full product lifecycle, from product launch preparation to the management of mature brands.

The platform forms part of the Vault CRM Suite, which also includes applications such as Events Management, Service Center, Campaign Manager, and Patient CRM. Veeva said the system combines industry-specific workflows, compliance features, and AI capabilities to support complex customer engagement across global biopharma markets.

Following the increasing adoption of Vault CRM, the company also updated the end-of-support timeline for its legacy Veeva CRM platform, moving the date from September 2030 to the end of December 2029.

PRNewswire

💬

WS Investor 03-04-26

Veeva Systems has announced the launch of Veeva eSource, a new application within its SiteVault platform aimed at eliminating paper-based processes and streamlining clinical trial data flow at research sites. The solution is designed to reduce manual work, improve data quality, and accelerate the movement of clinical data from sites to sponsors.

Veeva eSource enables direct digital data capture at the site, integrates with electronic health records (EHRs), and supports automated data transfer into electronic data capture (EDC) systems. By removing duplicate data entry and enabling bidirectional integration between eSource and EDC, the application reduces errors, minimizes quality control workload, and eliminates the need for traditional source data verification. The result is a more efficient clinical trial process that allows site staff and sponsors to focus more on patients and study execution.

The new application is part of the Veeva SiteVault platform and requires SiteVault CTMS for use. Veeva plans to make eSource available to early adopters in the second half of 2026, positioning it as a key step toward fully connected, straight-through clinical data flow across the trial ecosystem.

Source: PR Newswire

💬

The Investor 01-29-26

04-15-26WS News

04-14-26WS News

NYSE:VEEVFollow

5 Cash-Rich Fortresses with War Chests That Could Withstand the Market Chaos

NYSE:VEEV